Extended Bile Duct Resection Liver and Transplantation in Patients with Hilar Cholangiocarcinoma: Long-Term Results

被引:45
|
作者
Seehofer, Daniel [1 ]
Thelen, Armin
Neumann, Ulf P.
Veltzke-Schlieker, Winfried [2 ]
Denecke, Timm [3 ]
Kamphues, Carsten
Pratschke, Johann
Jonas, Sven
Neuhaus, Peter
机构
[1] Charite Campus Virchow, Dept Gen Visceral & Transplantat Surg, D-13353 Berlin, Germany
[2] Charite Campus Virchow, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany
[3] Charite Campus Virchow, Dept Radiol, D-13353 Berlin, Germany
关键词
SINGLE-CENTER EXPERIENCE; PERIHILAR CHOLANGIOCARCINOMA; HEPATOBILIARY MALIGNANCY; SURGICAL-TREATMENT; CARCINOMA; SURVIVAL; TUMORS; PREDICTORS; RECURRENCE; DISEASE;
D O I
10.1002/lt.21887
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
For patients with irresectable hilar cholangiocarcinoma, liver transplantation (LT) is currently being reassessed because of promising data for neoadjuvant radiochemotherapy. For increased radicality, hepatectomy in combination with pancreatic head resection [extended bile duct resection (EBDR)] was performed for irresectable hilar cholangiocarcinoma during our initial experience. EBDR and LT was performed in 16 patients between 1992 and 1998. No neoadjuvant or adjuvant treatment was performed. The Union Internationale Contre le Cancer stages were I (n = 6), IIA (5), IIB (3), and IV (2). To evaluate the suspected increase in surgical radicality, a matched pair analysis was performed with 8 patients undergoing LT for hilar cholangiocarcinoma without partial pancreatoduodenectomy. The 1-, 5-, and 10-year patient survival rates after EBDR were 63%, 38%, and 38%, respectively. Twelve patients died: 2 died because of postoperative complications, 8 died because of tumor recurrence, and 2 died while recurrence-free more than 10 years after transplantation. Among the 6 stage I patients, only 1 developed tumor recurrence, but 2 died because of postoperative complications. The following factors showed a trend toward inferior survival: distant metastases, positive lymph nodes, high carbohydrate antigen 19-9 levels, and preoperative percutaneous transhepatic cholangiodrainage. When all lymph node-negative patients were considered after the exclusion of perioperative deaths, 10-year survival was 56%. In conclusion, the overall long-term survival was relatively low in our inhomogeneous cohort but favorable in patients without metastases. However, because of the increased perioperative mortality, EBDR is not recommended as a standard procedure for hilar cholangiocarcinoma instead of LT alone. To further improve the results, other approaches such as (neo)adjuvant therapy have to be increasingly investigated. Liver Transpl 15: 1499-1507, 2009. (C) 2009 AASLD.
引用
收藏
页码:1499 / 1507
页数:9
相关论文
共 50 条
  • [21] Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate
    Seyama, Y
    Kubota, K
    Sano, K
    Noie, T
    Takayama, T
    Kosuge, T
    Makuuchi, M
    ANNALS OF SURGERY, 2003, 238 (01) : 73 - 83
  • [22] Investigation of long-term outcomes of bile duct stenosis after liver transplantation
    Suzuki, Ko
    Sato, Takamitsu
    Kurita, Yusuke
    Hasegawa, Sho
    Kato, Shingo
    Hosono, Kunihiro
    Endo, Itaru
    Kubota, Kensuke
    Nakajima, Atsushi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 160 - 160
  • [23] Robotic Resection of Type I Hilar Cholangiocarcinoma with Intrapancreatic Bile Duct Dissection
    May C. Tee
    Rushin D. Brahmbhatt
    Jan Franko
    Annals of Surgical Oncology, 2022, 29 : 964 - 969
  • [24] Regarding: Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma
    Schmelzle, Moritz
    Sucher, Robert
    Seehofer, Daniel
    Pratschke, Johann
    SURGERY, 2016, 159 (03) : 986 - 987
  • [25] Right hepatectomy with resection of caudate lobe and extrahepatic bile duct for hilar cholangiocarcinoma
    Endo, Itaru
    Matsuyama, Ryusei
    Taniguchi, Koichi
    Sugita, Mitsutaka
    Takeda, Kazuhisa
    Tanaka, Kuniya
    Shimada, Hiroshi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (03) : 216 - 224
  • [26] Reply to: "Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma"
    Hoffmann, Katrin
    Schemmer, Peter
    Buechler, Markus W.
    SURGERY, 2016, 159 (03) : 987 - 988
  • [27] Robotic Resection of Type I Hilar Cholangiocarcinoma with Intrapancreatic Bile Duct Dissection
    Tee, May C.
    Brahmbhatt, Rushin D.
    Franko, Jan
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (02) : 964 - 969
  • [28] Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma
    Sudan, D
    DeRoover, A
    Chinnakotla, S
    Fox, I
    Shaw, B
    McCashland, T
    Sorrell, M
    Tempero, M
    Langnas, A
    AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (08) : 774 - 779
  • [29] Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma
    Chauhan, Aakash
    House, Michael G.
    Pitt, Henry A.
    Nakeeb, Attila
    Howard, Thomas J.
    Zyromski, Nicholas J.
    Schmidt, C. Max
    Ball, Chad G.
    Lillemoe, Keith D.
    HPB, 2011, 13 (02) : 139 - 147
  • [30] RESEARCH INTO THE RESULTS OF RESECTION OF HILAR BILE-DUCT CANCER
    BOERMA, EJ
    SURGERY, 1990, 108 (03) : 572 - 580